WuXi AppTec removed from the US 1260H list under court order

The US Department of Defense removed WuXi AppTec Co., Ltd. from its Section 1260H list of Chinese military companies on November 9, 2026, following a preliminary injunction from a federal court. The Federal Register public-inspection notice says the department acted to comply with the order; the underlying lawsuit remains open, so the removal does not resolve every dispute over the designation.

Key points

• In WuXi AppTec Co., Ltd. v. U.S. Department of Defense, No. 1:26-cv-02069, the US District Court for the District of Columbia issued a preliminary injunction on August 7, barring the department from enforcing or giving effect to the designation while the case proceeds.
• Section 1260H is a statutory process for identifying and publishing Chinese military companies. A listing by itself is not a general ban on private companies doing business with the named firm.
• WuXi said the listing had no immediate effect on day-to-day operations. The court record also discussed evidence of canceled customer work, projects shifted to competitors and a supplier that suspended shipments, showing how a designation can affect commercial choices without automatically prohibiting them.

How the list works

Congress created Section 1260H in the FY2021 National Defense Authorization Act. It directs the Secretary of Defense to identify Chinese military companies operating in the United States, provide a list to Congress and publish an unclassified version in the Federal Register. The process is an executive-branch designation under defense law. It is not the Treasury Department’s sanctions list, and the designation alone does not freeze assets or prohibit every private transaction.

The June 10, 2026 Federal Register list added WuXi AppTec. The notice described the company as indirectly owned by the State-owned Assets Supervision and Administration Commission and indirectly affiliated with the State Administration for Science, Technology and Industry for National Defense and the People’s Liberation Army. WuXi rejected the characterization and sued the Department of Defense in June. Reuters reported that the company argued its designation lacked factual support and resulted from political pressure.

The consequences depend on what other laws, procurement rules and counterparties do with the designation. Some provisions can attach additional restrictions to entities on the list, while government contractors and private customers may also apply their own screening rules. WuXi provides research, testing and manufacturing services to drug and biotechnology developers, whose programs often rely on long-running vendor qualification and cross-border movement of samples, data and materials. The list can therefore become a commercial signal even where it does not itself order every customer to stop buying services. We previously covered another, legally distinct challenge involving the Pentagon’s designation powers in Alibaba’s preliminary injunction case.

What the court ordered

On August 7, 2026, the US District Court for the District of Columbia granted preliminary relief in case No. 1:26-cv-02069. The order barred the department from enforcing or giving effect to WuXi’s 1260H designation during the litigation. That is interim relief, not a final judgment on the merits. A preliminary injunction preserves a position while a court considers the claims; it does not itself settle how the department must handle future annual lists or prevent a new designation on a different record.

The court’s opinion discussed evidence WuXi submitted about commercial harm: customers had canceled contracts or collaborations, programs were paused or moved to competitors, and a supplier had suspended shipments. The opinion also described customers qualifying alternatives, a process that can make a lost relationship difficult to restore even if a designation is later blocked. Those are case-specific facts considered at the preliminary stage, not a measured estimate of losses across the pharmaceutical services industry.

The Pentagon’s public-inspection notice says it removed the company to comply with the injunction and reserves the department’s ability to designate WuXi again on additional or supplemental grounds. The notice was filed for public inspection on November 9 and scheduled for Federal Register publication on November 10. Reuters also reported the removal on November 9. That distinction matters: compliance with a court order changes the company’s current place on the list, but neither the notice nor the news report says the court has finished reviewing the underlying challenge.

Customers and suppliers

WuXi’s public update on its legal action said there was “no immediate impact” on day-to-day operations and that it remained able to serve customers as expected. That is the company’s account of overall operations. The court opinion’s discussion of canceled work and supplier disruption reflects evidence presented in litigation. Both can be true at once: a company can continue operating globally while individual customers or suppliers change particular programs in response to their own legal, procurement or risk policies.

The public materials reviewed here do not establish how many customers changed work, the value of any affected contracts, or whether any canceled program resumed after delisting. Nor does the November 9 notice automatically reinstate a customer contract. A sponsor considering a switch back still has to look at the relevant procurement terms, project status, quality audits, data and sample transfers, regulatory filings and qualification of any replacement provider. The court record supports the narrower point that switching suppliers can take effort and that disruption can persist; it does not prove that the entire industry is moving work in one direction.

This is why delisting should not be translated into a production-capacity or revenue estimate. The immediate legal obstacle created by the designation has been removed under the injunction, but customers may need to make their own documented decisions before work changes hands again. Companies with federal contracts should separately check whether a specific statute or contract clause incorporates the 1260H list. Private biopharma buyers should review their own screening commitments rather than assume that all business was either prohibited before November 9 or automatically cleared afterward.

What 1260H means

The list’s significance comes from its formal role in US defense policy and its possible use as a reference point in other rules or institutional policies. It should not be treated as synonymous with comprehensive sanctions. Whether a particular party faces a restriction depends on the law or contract that applies, the type of transaction and the agency implementing it. A private drug developer does not receive a universal purchase ban merely because a service provider appears on this list. At the same time, the absence of a blanket prohibition does not make the designation symbolic: the commercial evidence considered in WuXi’s case shows that customers and suppliers can reduce exposure on their own.

The dispute also raises questions about process: what evidence supports an asserted indirect relationship, how a company can challenge that evidence, and how much deference a court should give the Defense Department on national-security judgments. WuXi challenged its designation, and the court granted temporary relief. The department’s removal now complies with that order, while the final administrative-law dispute and the record behind the decision remain matters for the litigation. This case does not yet supply a general test for every company on the list.

What to watch

The immediate fact is a court-ordered removal, not a public announcement that the department has abandoned every underlying concern. The Federal Register notice explicitly preserves the option to designate WuXi on additional or supplemental grounds. The next relevant signals are the litigation’s further proceedings, any new rationale from the department and how WuXi is handled in a future annual list. The injunction also leaves broader questions about the statutory criteria and review process unsettled.

As of publication, we did not find a separate WuXi AppTec statement responding to the November 9 removal or a Hong Kong Stock Exchange announcement dated November 9 about it. The company’s earlier operations statement should not be mistaken for a response to this later court-compliance action.

For customers, the practical review is project by project: whether a contract refers to the list, whether a procurement approval needs to be refreshed, how far any replacement-provider qualification has progressed, and what formal steps would resume paused work. For policy watchers, the case shows courts reviewing the commercial consequences of a defense designation while leaving the agency’s statutory role and future decisions in play. It is a meaningful interim change for WuXi, but not a final answer for every company or customer affected by the 1260H framework.